Bayer is ready to spend money on more drug licensing agreements like last year’s deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.
Source:: Reuters – Business News
Newswire
- [ June 26, 2025 ] Hoth Therapeutics (NASDAQ: HOTH) HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects Newsmakers
- [ June 26, 2025 ] Lottery.com (NASDAQ: LTRY) Announces $10 Million Acquisition of GXR World Sports Assets to Power Global Launch of Sports.com Super App Newsmakers
- [ June 25, 2025 ] Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease. Healthcare
- [ June 24, 2025 ] Lottery.com (NASDAQ: LTRY) Appoints Tim Scoffham as CEO to Lead Global Expansion of Sports.com Media and Lottery.com International Newsmakers
- [ June 23, 2025 ] Lottery.com (NASDAQ: LTRY) Appoints Acclaimed Actor and Director Tamer Hassan as President of Sports.com Studios Newsmakers
- [ June 23, 2025 ] Core Gaming (NASDAQ: SYTA) Showcases Technological Strength as AI App Gains Traction Newsmakers
- [ June 23, 2025 ] Lottery.com (NASDAQ: LTRY) Regains Nasdaq Compliance as Stock Trading Activity Soars Newsmakers
- [ June 23, 2025 ] Hoth Therapeutics (NASDAQ: HOTH) to host KOL Event Spotlighting HT-001, Novel Therapy Newsmakers
- [ June 16, 2025 ] Sports.com (NASDAQ: LTRY) Enters Strategic Sponsorship with Racing Women to Accelerate the Future of Female Motorsport Newsmakers
- [ June 16, 2025 ] Lottery.com (NASDAQ: LTRY) and Sports.com Featured at Gateway with Triple-Driver Sponsorship Across IndyCar and IndyNXT Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.